tbuckley/cabot-search huggingface dataset:
Presidential Practice of Dermatology
Authors: Loren Zech, Bryce Turner, Scott A. Norton
Journal: JAMA Dermatology (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
PARANASAL CELL INFECTION AS A CAUSE OF INFECTIOUS ARTHRITIS
Authors: MILLARD F. ARBUCKLE
Journal: JAMA (1926)

In a paper read before this section at San Francisco in June, 1975, Hammond 1 stated that perhaps the chief problem to be considered in chronic infectious arthritis is the determination of the etiologic factor within the body. Furthermore, he thought it reasonable to suppose that if the arthritis is due to some suppurative process, the joint condition should be relieved, provided the etiologic factor is found and removed. After having called attention to the numerous possible sources of infection within the body, and the difficulties encountered in an effort to determine which one is responsible for the joint manifestations, he stated that he did not share the opinion of those workers in this field who believed that a recognizable focal infection was present in nearly all cases of chronic infectious arthritis, nor was he convinced that the removal of the focus of infection would necessarily cure a chronic arthritis
Effect of Denervation on Diameter and Reactivity of Arteries in the Bat Wing
Authors: MARY PURCELL WIEDEMAN
Journal: Circulation Research (1955)

Responsiveness of the arterial vessels to intravenous and topically applied epinephrine was determined before and after denervation. Responsiveness to injected epinephrine increased 14 days after denervation; responsiveness to topically applied epinephrine was unaffected by denervation; arterial vessels remained dilated in excess of three weeks following denervation.
Nicardipine as antihypertensive therapy in liver transplant recipients: Results of long-term use
Authors: C Duvoux, D Cherqui, V Di Martino, J Métreau, A Salvat, J Lauzet, P Fagniez, D Dhumeaux
Journal: Hepatology (1997)

Arterial hypertension is frequent in liver transplant recipients on cyclosporine A (CsA). Nicardipine is a calcium channel blocker (CCB) that has been shown to be efficient in controlling postoperative hypertension. However, its use has been limited in organ recipients because of its reported interaction with CsA metabolism. In this report, we studied the results of the long-term use of nicardipine after liver transplantation. Forty-nine consecutive liver transplant recipients with a follow-up longer than 2 years were studied. Immunosuppressive regimen was based on CsA and prednisone. Patients with immediate postoperative hypertension received intravenous nicardipine, secondarily switched to oral nicardipine (group 1, n = 27). Patients with delayed hypertension (i.e., >2 weeks posttransplant) received other antihypertensive drugs which did not interact with CsA metabolism. These patients and those without hypertension formed group 2 (n = 22). The two groups were similar for age, sex, body weight, and transplantation indications. Interaction of nicardipine with CsA metabolism was confirmed. Whereas cyclosporine blood levels were similar in both groups at any time during the study, the mean cyclosporine daily dose required to achieve such levels was 30% lower in group 1 compared with group 2 (P < .01). This resulted in a significant cost-containment. The use of nicardipine was not associated with an increased incidence of graft rejection or CsA toxicity episodes. The results in liver transplant recipients showed that nicardipine interacts with CsA metabolism, leading to a 30% reduction in CsA dose and does not increase the risk of CsA toxicity or graft rejection. Nicardipine can be used safely for the treatment of arterial hypertension after liver transplantation with a potential cost-containment.
EARLY PHYSICIAN FOLLOW-UP AND 30-DAY READMISSION AMONG MEDICARE BENEFICIARIES HOSPITALIZED WITH HEART FAILURE: DATA FROM OPTIMIZE-HF AND GWTG-HF
Authors: Adrian F. Hernandez, Melissa A. Greiner, Gregg C. Fonarow, Bradley G. Hammill, Paul A. Heidenreich, Clyde Yancy, Eric D. Peterson, Lesley H. Curtis
Journal: Journal of the American College of Cardiology (2010)
TO BLEED OR NOT TO BLEED IN PNEUMONIA?Read in the Section of Practice of Medicine, at the Forty-fourth Annual Meeting of the American Medical Association.
Authors: JOHN NORTH
Journal: JAMA (1893)

Fifty years ago when pneumonia was recognized as a pure and simple local inflammation of the lungs this question would have been answered in the affirmative, and no reputable physician would dare raise his voice against it. But in this, the last decade of the nineteenth century, the physician that resorts to bleeding in pneumonia offers an apology for so doing. Our modern views of pneumonia have undergone a radical change during the past few decades. The histological structure and the phynelogical function of the lungs are better understood than they were fifty years ago. Our knowledge of the pathological anatomy and the pathological functions of the lungs have undergone wonderful changes during that time. The bacteriologist with his cultures, his microscopic and microörgans the chemist with his reagents, his test tubes and ptomaines have greatly changed our opinions in regard to the causes and progress of pneumonia, and with
The antiarrhythmic effect of nortriptyline in cardiac patients with ventricular premature depolarizations
Authors: Elsa-Grace V. Giardina, Thomas Barnard, Lynne Johnson, Alan L. Saroff, J. Thomas Bigger, May Louie
Journal: Journal of the American College of Cardiology (1986)

The effect of nortriptyline against ventricular arrhythmias was determined in 16 cardiac patients with 30 or more ventricular premature depolarizations per hour. Nortriptyline was administered orally, 0.5 mg/kg body weight per day, and increased by 0.5 mg/kg per day every third day until ventricular premature depolarizations were suppressed (≥80%), adverse effects occurred or a total daily dose of 3.5 mg/kg per day was given. Each patient had daily 24 hour continuous electrocardiograms, 12 lead standard electrocardiograms and physical examination; blood pressure was measured in the supine and standing position four times a day. Each patient also had radionuclide angiography at rest to measure ejection fraction before and at the effective or maximal dose. Thirteen patients (81%) had an antiarrhythmic response and 11 met the study criterion of at least 80% improvement. Doses ranged from 50 to 200 mg/day (mean 111 ± 45), steady state plasma concentration ranged from 46 to 410 ng/ml (mean 153 ± 96) and half-life of elimination of nortriptyline was 4 to 22 hours (mean 13 ± 4). Administration of nortriptyline did not depress mean ejection fraction (before 42 ± 12%, after 41 ± 12%); it was associated with an orthostatic decrease in systolic blood pressure (mean -13 ± 13 mm Hg). Nortriptyline is an effective antiarrhythmic agent which may be given twice a day even in patients with impaired ventricular function.
Rupture of a Pulmonary Artery Branch during Right Heart Catheterization
Authors: Azzat Ali, Mohammed Kousha, Ayman Soubani
Journal: American Journal of Respiratory and Critical Care Medicine (2011)

Figure 1 is a fluoroscopic image of the pulmonary angiogram showing extravasation of contrast media to the left upper lobe and a 2.5-cm pseudoaneurysm of a segmental branch of the left pulmonary artery. Figure 2 is a fluoroscopic image of the pulmonary angiogram showing multiple metallic coils in the pseudo-aneurysm of the segmental branch of the left pulmonary artery with no further extravasation of contrast media to the left upper lobe.
Ethics Manual
Authors: Lois Snyder, Cathy Leffler
Journal: Annals of Internal Medicine (2005)

Medicine, law, and social values are not static. Reexamining the ethical tenets of medical practice and their application in new circumstances is a necessary exercise. The fifth edition of the College's Ethics Manual covers emerging issues in medical ethics and revisits old ones. It reflects on many of the ethical tensions faced by internists and their patients and attempts to shed light on how existing principles extend to emerging concerns. In addition, by reiterating ethical principles that have provided guidance in resolving past ethical problems, the Manual may help physicians avert future problems. The Manual is not a substitute for the experience and integrity of individual physicians, but it may serve as a reminder of the shared obligations and duties of the medical profession. *Current and former members of the Ethics and Human Rights Committee who developed this fifth edition of the Manual: William E. Golden, MD (Chair); Harmon H. Davis, II, MD (Vice Chair); David A. Fleming, MD; Susan E. Glennon, MD; Vincent E. Herrin, MD; Virginia L. Hood, MD, MPH; Jay A. Jacobson, MD; Stephen R. Jones, MD; Allen S. Keller, MD; Joanne Lynn, MD; Clement J. McDonald, MD; Paul S. Mueller, MD; Steven Z. Pantilat, MD; David W. Potts, MD; and Daniel P. Sulmasy, OFM, MD, PhD. Approved by the Board of Regents on 17 July 2004.
Use of human lung tissue for studies of structural changes associated with chronic ozone exposure: opportunities and critical issues.
Authors: M Lippmann
Journal: Environmental Health Perspectives (1993)

Definitive information on the chronic effects of exposure to ozone (O3) in humans is not available. There is a strong concern that ozone could produce chronic lung damage in humans on the basis that exposures are ubiquitous at levels that produce transient symptoms, function deficits, and lung inflammation in humans and chronic lung damage in laboratory animals. Both prospective and national population surveys suggest an association between chronic O3 exposure and reduced lung function, and a pilot investigation of autopsied lungs of accident victims in Los Angeles reported an unexpectedly high incidence of disease in the centriacinar region, the lung region known to receive the highest dose of inhaled O3. This paper discusses the advantages and limitations of further studies of structural changes in human lung tissue in relation to chronic O3 exposure. The major advantages of such studies are that a) measurable effects may be related to realistic chronic exposures, b) the effects may be described quantitatively and compared directly to those obtained in chronic animal inhalation exposures, and c) evidence for chronic effects may be obtained much more rapidly than in prospective studies. The major limitations are the difficulties in obtaining sufficient reliable information on residential history, physical activity out-of-doors, and smoking and other confounding exposures to lung irritants from next of kin, and limited availability of adequate air quality data for determining ambient concentrations at places of residence and/or outdoor exercise. The paper also discusses approaches to minimizing these limitations in the design of specific studies.
Bleomycin and Mild Renal Failure
Authors: V. J. HARVEY
Journal: Annals of Internal Medicine (1986)

Letters and Corrections1 December 1986Bleomycin and Mild Renal FailureV. J. HARVEY, M.D., P. I. THOMPSON, M.B., Ch.B.V. J. HARVEY, M.D.Search for more papers by this author, P. I. THOMPSON, M.B., Ch.B.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-105-6-976_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Significant progress has been made in the treatment of diffuse large-cell lymphoma in recent years with the use of several intensive combination chemotherapy programs. In 1985, Klimo and Connors (1) reported a study in 61 patients treated with MACOP-B combination chemotherapy (methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin) with impressive early results. This regimen was modified several times during its development, including the substitution of bleomycin for methotrexate in patients whose creatinine clearance was less than 60 mL/min.We are concerned that this modification is potentially dangerous and should not be recommended. It may have...References1. KLIMOCONNORS PJ. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985;102:596-602. LinkGoogle Scholar2. CONNORSKLIMO JP. MACOP-B 12 week chemotherapy for lymphoma: update and additional observations [Abstract 752]. Proc Am Soc Clin Oncol. 1986;5:192. Google Scholar3. OKENCROOKEELSONSTRONGSHAFER MSMJR. Pharmacokinetics of bleomycin after IM administration in man. Cancer Treat Rep. 1981;65:485-9. MedlineGoogle Scholar4. DALGLEISHWOODSLEVI ARJ. Bleomycin pulmonary toxicity: its relationship to renal dysfunction. Med Pediatr Oncol. 1984;12:313-7. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: V. J. HARVEY, M.D.; P. I. THOMPSON, M.B., Ch.B.Affiliations: Auckland Hospital Auckland New Zealand PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 1986Volume 105, Issue 6Page: 976-976KeywordsCombination chemotherapyCreatinineCyclophosphamideDiffuse large B-cell lymphomaMethotrexateRenal failure ePublished: 1 December 2008 Issue Published: 1 December 1986 PDF downloadLoading ...
Is unselective biochemical urine testing cost effective?
Authors: J F Zilva
Journal: BMJ (1985)

Clinitek Auto 2000, and Boehringer Mannheim Urotron-may eliminate many of the avoidable errors commonly encountered.Nevertheless, I believe that this would be impracticable, expen- sive, and undesirable.Urine analysis fulfils many of the criteria of the ideal laboratory test, being simple to perform, inexpensive, easy to interpret, quick, applicable in many clinical settings, and able to be carried out in a wide variety of situations.The problems that arise with urine analysis generally occur for explicable reasons.These difficulties are common enough to make current standards unsatis- factory.I urge the adoption of the quality control strategies outlined here with a view to generally improving analytical performance.This can only result in better clinical care.
<i>In Utero</i> Pesticide Exposure and Leukemia in Brazilian Children &lt; 2 Years of Age
Authors: Jeniffer Dantas Ferreira, Arnaldo Cézar Couto, Maria S. Pombo-de-Oliveira, Sergio Koifman
Journal: Environmental Health Perspectives (2012)

An association between pesticide exposure and cancer has been suggested. Infant leukemia is a rare neoplasm and its association with maternal pesticide exposure has been poorly explored.We investigated the association between pesticide exposure during pregnancy and leukemia in children < 2 years of age.A hospital-based case-control study was carried out in 13 Brazilian states during 1999-2007. Mothers of 252 cases and those of 423 controls were interviewed. Information on pesticide exposures 3 months before pregnancy, throughout pregnancy, and during breastfeeding was obtained. Unconditional logistic regression was used to estimate adjusted odds ratios (aORs) for associations between pesticide exposures and leukemia.Associations with ever use of pesticides during pregnancy were observed for acute lymphoid leukemia (ALL) (aOR = 2.10; 95% CI: 1.14, 3.86) and acute myeloid leukemia (AML) (aOR = 5.01; 95% CI: 1.97, 12.7) in children 0-11 months of age, and with ALL (aOR = 1.88; 95% CI: 1.05, 5.23) at 12-23 months of age. According to reported maternal exposure to permethrin, higher risk estimates were verified for children 0-11 months of age (aOR = 2.47; 95% CI: 1.17, 5.25 for ALL; and aOR = 7.28; 95% CI: 2.60, 20.38 for AML). Maternal pesticide exposure related to agricultural activities showed an aOR of 5.25 (95% CI: 1.83, 15.08) for ALL, and an aOR of 7.56 (95% CI: 1.83, 31.23) for AML.These results support the hypothesis that pesticide exposure during pregnancy may be involved in the etiology of acute leukemia in children < 2 years of age.
Acute Pharyngotonsillitis Caused by Herpesvirus Type 2
Authors: Edward J. Young
Journal: JAMA (1978)

HERPES simplex virus (HSV) type 1 is now recognized as a common nonbacterial cause of acute pharyngitis in young adults.1Herpes simplex virus type 2 is most often associated with urogenital infections of men or women and is generally transmitted venereally.4Acute exudative pharyngitis and tonsillitis developed in a bisexual man following oral-genital sex with male and female partners. Herpes simplex virus type 2 was recovered from the pharynx and identified in a biopsy specimen of tonsillar tissue.  Report of a Case  A 25-year-old bisexual man had fever, chills, odynophagia, and inability to swallow oral secretions for four days. He had received one dose of intramuscularly administered penicillin and had taken ampicillin orally for three days without relief. He had engaged in oral-genital sex with male and female partners ten days previously. He denied previous oral or genital herpes but had been treated for syphilis in the past.
Fluticasone propionate aqueous nasal spray reduces inflammatory cells in unchallenged allergic nasal mucosa: Effects of single allergen challenge
Authors: Adriaan Holm, Mariska Dijkstra, Alex Kleinjan, Lies-anne Severijnena, Simone Boksa, Paul Mulder, Wytske Fokkens
Journal: Journal of Allergy and Clinical Immunology (2001)
HOXB13 protein expression predicts the benefit of tamoxifen treatment in breast cancer patients.
Authors: P Jerevall, A Jansson, T Fornander, L Skoog, B Nordenskjöld, O Stål
Journal: Cancer Research (2009)

Abstract Abstract #6038 Background: The two-gene expression ratio HOXB13:IL17BR, originally from a microarray analysis, has been shown to be indicative of clinical outcome in the setting of adjuvant tamoxifen monotherapy of breast cancer, with a high ratio associated with decreased disease-free survival. Analysis of a cohort of breast cancer patients randomized to 2 or 5 years of adjuvant tamoxifen therapy showed that the two-gene ratio and expression of the HOXB13 gene alone were predictive of the benefit of prolonged tamoxifen treatment. Patients with tumors expressing HOXB13 at high levels were unresponsive to prolonged adjuvant treatment, suggesting that this gene is involved in tamoxifen resistance. It is suggested that a high two-gene ratio may indicate impaired ER signaling, which is known to predict resistance to tamoxifen. To our knowledge, there are no studies investigating the HOXB13 protein levels in breast cancer.&amp;#x2028; Methods: We have analyzed the protein expression of HOXB13 with immunohistochemistry in tumor samples from 912 postmenopausal node negative breast cancer patients randomized to 2 years of tamoxifen or no endocrine treatment. After 2 years, recurrence-free patients were randomized to 3 more years of tamoxifen, or no further therapy. This selection enabled us to investigate the treatment predictive value of HOXB13.&amp;#x2028; Results: Data on HOXB13 protein expression were obtained from 866 patients (see table). Tamoxifen treated patients with estrogen receptor (ER) positive tumors expressing none or low levels of HOXB13 had a clear benefit from tamoxifen in terms of longer distant recurrence-free survival (hazard ratio (HR) 0.37, 95% CI 0.23-0.60, p=0.000048). However, for patients with a high or intermediate HOXB13 tumor expression, tamoxifen did not prolong the distant recurrence-free survival compared to the untreated patients (HR=0.83, 95% CI 0.45-1.54, p=0.55). The interaction between HOXB13 expression and benefit from tamoxifen was statistically significant (p=0.046). HOXB13 did not have any prognostic value among systemically untreated patients.&amp;#x2028; &amp;#x2028; Conclusions: HOXB13 protein level may be used as a predictive marker for tamoxifen treatment, but does not have any prognostic value. Patients with a high expression of HOXB13 do not seem to benefit from tamoxifen. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 6038.
Polychlorinated biphenyl exposure and effects in transformer repair workers.
Authors: E A Emmett
Journal: Environmental Health Perspectives (1985)

Fifty-five present and past transformer repair workers exposed to polychlorinated biphenyls (PCBs) and 56 unexposed comparison workers were evaluated in a clinical-epidemiologic study. The groups were similar in most demographic variables. Adipose tissue lipid and serum PCBs concentrations were higher in current exposed workers (geometric means adipose 2.1 ppm, serum 12.2 ppb). Concentrations in comparison (0.6 ppm and 4.6 ppb) and previously exposed (0.83 ppm and 5.9 ppb) workers were lower. Statistically significant differences in serum albumin and lactic dehydrogenase, but not in other liver function tests, were seen between the exposed and comparison groups; however, after adjustment for confounding variables, no correlations were observed between liver function tests and either adipose or serum PCBs concentrations. Statistically significant correlation both before and after adjustment for confounding variables were seen with adipose PCBs and 24-hr urinary 17-hydroxycorticosteroid excretion and with serum PCBs and serum gamma-glutamyl transpeptidase. Both associations could reflect microsomal enzyme induction among other possibilities. No differences were seen in fasting serum triglycerides, total cholesterol, LDL, HDL or VLDL cholesterol between the two exposure groups. A statistically significant correlation between serum PCBs and serum triglycerides, total cholesterol, and VLDL cholesterol was removed by adjusting for confounding variables. No correlation was seen between adipose PCBs concentrations and any serum lipid component. Partition phenomena could account for these findings.(ABSTRACT TRUNCATED AT 250 WORDS)
Young Adult Oncology: The Patients and Their Survival Challenges
Authors: A. Bleyer
Journal: CA A Cancer Journal for Clinicians (2007)

One in every 168 Americans develops invasive cancer between age 15 to 30 years. During this age interval, cancer is unique in the distribution of types that occur and rarely related to either environmental carcinogens, a recognizable inherited predisposition, or a family cancer syndrome. Patients in this age group have the lowest rate of health insurance coverage, frequent delays in diagnosis, and the lowest accrual to clinical trials. Their psychosocial needs are unique and generally less well attended to than in any other age group. Despite an intrinsically equal ability to tolerate chemotherapy, older adolescents and young adults frequently receive lower dose intensities than do younger patients, and at times less than in older patients. Whereas the 15- to 29-year age group once had a better overall survival rate than either younger or older patients, a relative lack of progress has resulted in the majority of cancers in the age group having a worse overall survival rate than in younger patients, and several of these having a worse prognosis than in older patients. Against this background, young adults with cancer have unique survival challenges—medically, psychosocially, and economically—that are now beginning to be appreciated and addressed with a national initiative.